• Incanthera

    Revolutionary Cancer Therapies

    Creating an environment in which cancer cannot survive

  • Incanthera

    Excellence in Oncology Research

    Originating from world-recognised, research-led Universities

  • Incanthera

    Delivering Improved Patient Outcomes

    Targeted technologies yielding greater efficacy with fewer side effects

Company Overview

  • UK oncology focused, targeted drug development company

  • Acquiring, preparing and commercialising new oncology technologies

  • Multiple asset portfolio

  • First commercial deal for Company’s asset (EP0015) signed June 2017

  • Near to market asset – possible commercialisation within 18 months

  • Lean outsourced business model

  • Experienced, multi-skilled team

  • Diverse portfolio providing newsflow opportunities

Our Story

Cancer Today

  • 1 in 2 patients survive cancer for ten or more years (CRUK)
  • 24% to 50% cancer survival in the UK has doubled in the last forty years
  • Incanthera

    Technology Pipeline

    Incanthera’s current pipeline is oncology focussed, where drug development leverages novel targeting strategies with known anti-cancer modes of action.

    View all technologies

Meet The Team

Highly experienced team drawn from commercial, scientific and regulatory backgrounds

Find out more about our team